US4233284A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stabilized radiographic scanning agents
Assignee: Mallinckrodt Inc
•
Filing: 1978-03-31
•
Granted: 1980-11-11
•
Expires: 1998-03-31
Abstract
Abstract Stable compositions, useful as technetium-99m-based scintigraphic agents, comprise gentisic acid or a pharmaceutically-acceptable salt or ester thereof in combination with a pertechnetate reducing agent or dissolved in pertechnetate-99m (99mTcO4-) solution. The compositions are especially useful in combination with a phosphate or phosphonate material which carries the radionuclide to bone, thus providing a skeletal imaging agent.
Inventors
- 👤 Mahdi B. Fawzi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 17:28
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/02; A61K51/025; A61K51/04; A61K2123/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
37 words
A stable composition, useful in the preparation of technetium-99m-based radiographic scanning agents, comprising: a pertechnetate reducing agent; and a stabilizing amount of a gentisate stabilizer selected from gentisic acid and the soluble, pharmaceutically-acceptable salts and esters thereof.
Claim 2
Dependent Claim
37 words
A stable composition, useful in the preparation of technetium-99m-based radiographic scanning agents, comprising: a pertechnetate reducing agent; and a stabilizing amount of a gentisate stabilizer selected from gentisic acid and the soluble, pharmaceutically-acceptable salts and esters thereof.
Claim 3
Dependent Claim
25 words
A composition according to claim 1, comprising a weight ratio of gentisate stabilizer to reducing agent in the range of about 20:1 to about 1:20.
Claim 4
Dependent Claim
25 words
A composition according to claim 2, wherein the ratio of stabilizer to reducing agent is in the range of from about 10:1 to about 1:1.
Claim 5
Dependent Claim
20 words
A composition according to claim 3, wherein the gentisate stabilizer is selected from gentisic acid or a pharmaceutically-acceptable salt thereof.
Claim 6
Dependent Claim
25 words
A composition according to claim 1, wherein the pertechnetate reducing agent is selected from the group consisting of the soluble stannous, chromous and ferrous salts.
Claim 7
Dependent Claim
25 words
A composition according to claim 5 wherein the pertechnetate reducing agent is selected from the group consisting of stannous chloride, chromous chloride and ferrous sulfate.
Claim 8
Dependent Claim
34 words
A composition according to claim 1 wherein the reducing agent is stannous chloride, the gentisate is gentisic acid or sodium gentisate, and the weight ratio of gentisate:SnCl 2 is about 5:1 to about 1:1.
Claim 9
Dependent Claim
11 words
A composition according to claim 1, additionally comprising an organ-specific carrier.
Claim 10
Dependent Claim
13 words
A composition according to claim 8 wherein the organ-specific carrier is an organophosphonate.
Claim 11
Dependent Claim
31 words
A composition according to claim 9 wherein the organophosphonate is selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid, methanediphosphonic acid, dichloromethanediphosphonic acid, methanehydroxydiphosphonic acid, and the soluble salts and esters thereof.
Claim 12
Dependent Claim
35 words
A composition according to claim 10 wherein the pertechnetate reducing agent is stannous chloride, the organ-specific carrier is a sodium salt form of ethane-1-hydroxy-1,1-diphosphonic acid, and the gentisate stabilizer is sodium gentisate or gentisic acid.
Claim 13
Dependent Claim
35 words
A composition according to claim 10 wherein the pertechnetate reducing agent is stannous chloride, the organ-specific carrier is a sodium salt form of methanediphosphonic acid, and the gentisate stabilizer is sodium gentisate or gentisic acid.
Claim 14
Dependent Claim
35 words
A composition according to claim 10 wherein the pertechnetate reducing agent is stannous chloride, the organ-specific carrier is a sodium salt form of dichloromethanediphosphonic acid, and the gentisate stabilizer is sodium gentisate or gentisic acid.
Claim 15
Dependent Claim
35 words
A composition according to claim 10 wherein the pertechnetate reducing agent is stannous chloride, the organ-specific carrier is a sodium salt form of methanehydroxydiphosphonic acid, and the gentisate stabilizer is sodium gentisate or gentisic acid.
Claim 16
Dependent Claim
12 words
A composition according to claim 9 wherein the organophosphonate is a 3-aminopropane-1-hydroxy-1,1-diphosphonate.
Claim 17
Dependent Claim
15 words
A composition according to claim 8 wherein the organ-specific carrier is a water-soluble inorganic phosphate.
Claim 18
Dependent Claim
14 words
A composition according to claim 16 wherein the inorganic phosphate is a sodium pyrophosphate.
Claim 19
Dependent Claim
37 words
A composition useful in the preparation of technetium-99m-based radiographic scanning agents, comprising: and oxidized pertechnetate solution having dissolved therein a stabilizing amount of a gentisate stabilizer selected from gentisic acid or a pharmaceutically-acceptable salt or ester thereof.
Claim 20
Dependent Claim
37 words
A composition useful in the preparation of technetium-99m-based radiographic scanning agents, comprising: and oxidized pertechnetate solution having dissolved therein a stabilizing amount of a gentisate stabilizer selected from gentisic acid or a pharmaceutically-acceptable salt or ester thereof.
Claim 21
Dependent Claim
25 words
A composition according to claim 18, comprising an oxidized pertechnetate solution having dissolved therein no more than about 0.1% by weight of a gentisate stabilizer.
Claim 22
Dependent Claim
27 words
A composition according to claim 19, comprising an oxidized pertechnetate solution having dissolved therein no more than about 0.1%, by weight, of sodium gentisate or gentisic acid.
Claim 23
Independent Claim
44 words
A method of preparing a stabilized technetium-99m-based scanning agent, comprising codissolving a stabilizing amount of a gentisate stabilizer selected from gentisic acid or a pharmaceutically-acceptable salt or ester thereof with an aqueous solution of radioactive technetium in the +3, +4 or +5 valence state.
Claim 24
Independent Claim
44 words
A method of preparing a stabilized technetium-99m-based scanning agent, comprising codissolving a stabilizing amount of a gentisate stabilizer selected from gentisic acid or a pharmaceutically-acceptable salt or ester thereof with an aqueous solution of radioactive technetium in the +3, +4 or +5 valence state.
Claim 25
Dependent Claim
15 words
A method according to claim 21 wherein an organ-seeking carrier is included in the solution.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-11-11 | 1984-05-12 | 1984-11-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-11-11 | 1988-05-12 | 1988-11-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-11-11 | 1992-05-12 | 1992-11-11 | $7700.00 | Window Closed / Lapsed |